Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9UHA7

UPID:
IL36A_HUMAN

ALTERNATIVE NAMES:
FIL1 epsilon; Interleukin-1 epsilon; Interleukin-1 family member 6

ALTERNATIVE UPACC:
Q9UHA7; B2RAD9; Q53SR7; Q5BLR4; Q7RTZ8

BACKGROUND:
Interleukin-36 alpha, identified by the alternative names FIL1 epsilon and Interleukin-1 family member 6, is integral to initiating inflammatory responses. It binds to the IL1RL2/IL-36R receptor, triggering NF-kappa-B and MAPK pathways in target cells. This action is pivotal in skin inflammation, affecting keratinocytes, dendritic cells, and T-cells, and leads to the production of various chemokines and pro-inflammatory cytokines.

THERAPEUTIC SIGNIFICANCE:
The exploration of Interleukin-36 alpha's function offers promising avenues for therapeutic intervention. Its critical role in inflammatory processes and immune cell regulation makes it a compelling candidate for developing treatments for inflammatory conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.